Azithramycine
Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.
Cross Reference
Introduction
To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Azithramycine?
Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (156)
- Clin. Infect. Dis. (64)
- J. Antimicrob. Chemother. (50)
- Others (435)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Azithramycine
PubChem Associated disorders and diseases
What pathways are associated with Azithramycine
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Azithramycine?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (66)
- J. Antimicrob. Chemother. (25)
- Clin. Infect. Dis. (13)
- Others (151)
| Location | Cross reference | Weighted score | Related literatures |
|---|
What functions are associated with Azithramycine?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Azithramycine?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
What genes are associated with Azithramycine?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (44)
- J. Antimicrob. Chemother. (18)
- Clin. Infect. Dis. (10)
- Others (126)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Azithramycine?
Mouse Model
Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).
Knock-out
Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).
Tissue Model
Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
NCBI Entrez Crosslinks
All references with Azithramycine
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Euba B et al. | Relationship between azithromycin susceptibility and administration efficacy for nontypeable Haemophilus influenzae respiratory infection. | 2015 | Antimicrob. Agents Chemother. | pmid:25712355 |
| Shigemura K et al. | Azithromycin resistance and its mechanism in Neisseria gonorrhoeae strains in Hyogo, Japan. | 2015 | Antimicrob. Agents Chemother. | pmid:25712352 |
| Imamura Y et al. | Azithromycin inhibits MUC5AC production induced by the Pseudomonas aeruginosa autoinducer N-(3-Oxododecanoyl) homoserine lactone in NCI-H292 Cells. | 2004 | Antimicrob. Agents Chemother. | pmid:15328111 |
| Liu P et al. | Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimen. | 2007 | Antimicrob. Agents Chemother. | pmid:17060516 |
| Soltow SM and Brenner GM | Synergistic activities of azithromycin and amphotericin B against Naegleria fowleri in vitro and in a mouse model of primary amebic meningoencephalitis. | 2007 | Antimicrob. Agents Chemother. | pmid:17060522 |
| Beringer P et al. | Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis. | 2005 | Antimicrob. Agents Chemother. | pmid:16304166 |
| Ulrich M et al. | Moxifloxacin and azithromycin but not amoxicillin protect human respiratory epithelial cells against streptococcus pneumoniae in vitro when administered up to 6 hours after challenge. | 2005 | Antimicrob. Agents Chemother. | pmid:16304181 |
| Grinwis ME et al. | Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients. | 2010 | Antimicrob. Agents Chemother. | pmid:20404127 |
| Loreto ES et al. | New insights into the in vitro susceptibility of Pythium insidiosum. | 2014 | Antimicrob. Agents Chemother. | pmid:25223997 |
| Schmalstieg AM et al. | The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance. | 2012 | Antimicrob. Agents Chemother. | pmid:22751536 |
| Gorby GL and McGee ZA | Antimicrobial interference with bacterial mechanisms of pathogenicity: effect of sub-MIC azithromycin on gonococcal piliation and attachment to human epithelial cells. | 1990 | Antimicrob. Agents Chemother. | pmid:1982402 |
| Bonnet M and Van der Auwera P | Preincubation of Haemophilus influenzae with subinhibitory concentrations of macrolides: influence on human neutrophil chemiluminescence. | 1993 | Antimicrob. Agents Chemother. | pmid:8390808 |
| Gordillo ME et al. | In vitro activity of azithromycin against bacterial enteric pathogens. | 1993 | Antimicrob. Agents Chemother. | pmid:8390813 |
| Singh S et al. | Antimycobacterial drugs modulate immunopathogenic matrix metalloproteinases in a cellular model of pulmonary tuberculosis. | 2014 | Antimicrob. Agents Chemother. | pmid:24890593 |
| Tsitsika A et al. | Single-oral-dose azithromycin prophylaxis against experimental streptococcal or staphylococcal aortic valve endocarditis. | 2000 | Antimicrob. Agents Chemother. | pmid:10817749 |
| Scorneaux B et al. | Effect of recombinant human gamma interferon on intracellular activities of antibiotics against Listeria monocytogenes in the human macrophage cell line THP-1. | 1996 | Antimicrob. Agents Chemother. | pmid:8723471 |
| Bin XX et al. | Effect of azithromycin plus rifampin versus amoxicillin alone on eradication and inflammation in the chronic course of Chlamydia pneumoniae pneumonitis in mice. | 2000 | Antimicrob. Agents Chemother. | pmid:10817751 |
| Pacifico L et al. | Comparative efficacy and safety of 3-day azithromycin and 10-day penicillin V treatment of group A beta-hemolytic streptococcal pharyngitis in children. | 1996 | Antimicrob. Agents Chemother. | pmid:8849215 |
| Kobuchi S et al. | Transport of Azithromycin into Extravascular Space in Rats. | 2016 | Antimicrob. Agents Chemother. | pmid:27600045 |
| Jaruratanasirikul S et al. | Distribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye. | 1996 | Antimicrob. Agents Chemother. | pmid:8851625 |
| Goldman RC and Capobianco JO | Role of an energy-dependent efflux pump in plasmid pNE24-mediated resistance to 14- and 15-membered macrolides in Staphylococcus epidermidis. | 1990 | Antimicrob. Agents Chemother. | pmid:1963291 |
| Navarro G et al. | Image-based 384-well high-throughput screening method for the discovery of skyllamycins A to C as biofilm inhibitors and inducers of biofilm detachment in Pseudomonas aeruginosa. | 2014 | Antimicrob. Agents Chemother. | pmid:24295976 |
| Mallegol J et al. | Antimicrobial activity of solithromycin against clinical isolates of Legionella pneumophila serogroup 1. | 2014 | Antimicrob. Agents Chemother. | pmid:24277019 |
| Blais J et al. | Inhibition of Toxoplasma gondii protein synthesis by azithromycin. | 1993 | Antimicrob. Agents Chemother. | pmid:8215287 |
| Dever LL et al. | Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi. | 1993 | Antimicrob. Agents Chemother. | pmid:8215288 |
| Edelstein PH and Edelstein MA | In vitro activity of azithromycin against clinical isolates of Legionella species. | 1991 | Antimicrob. Agents Chemother. | pmid:1849708 |
| Itaqui SR et al. | In Vitro Synergism between Azithromycin or Terbinafine and Topical Antimicrobial Agents against Pythium insidiosum. | 2016 | Antimicrob. Agents Chemother. | pmid:27216049 |
| Ohtani H et al. | Comparative pharmacodynamic analysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in rats. | 2000 | Antimicrob. Agents Chemother. | pmid:10991836 |
| Matic V et al. | Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin. | 2004 | Antimicrob. Agents Chemother. | pmid:15504828 |
| Kosowska K et al. | Activities of two novel macrolides, GW 773546 and GW 708408, compared with those of telithromycin, erythromycin, azithromycin, and clarithromycin against Haemophilus influenzae. | 2004 | Antimicrob. Agents Chemother. | pmid:15504829 |
| Berry V et al. | Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae. | 1998 | Antimicrob. Agents Chemother. | pmid:9835514 |
| Niki Y et al. | In vitro and in vivo activities of azithromycin, a new azalide antibiotic, against chlamydia. | 1994 | Antimicrob. Agents Chemother. | pmid:7840560 |
| Freeman CD et al. | Intracellular and extracellular penetration of azithromycin into inflammatory and noninflammatory blister fluid. | 1994 | Antimicrob. Agents Chemother. | pmid:7840585 |
| Chisholm SA et al. | High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes. | 2010 | Antimicrob. Agents Chemother. | pmid:20585125 |
| Deshpande D et al. | Azithromycin Dose To Maximize Efficacy and Suppress Acquired Drug Resistance in Pulmonary Mycobacterium avium Disease. | 2016 | Antimicrob. Agents Chemother. | pmid:26810646 |
| Chinh NT et al. | A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever. | 2000 | Antimicrob. Agents Chemother. | pmid:10858343 |
| Miltner EC and Bermudez LE | Mycobacterium avium grown in Acanthamoeba castellanii is protected from the effects of antimicrobials. | 2000 | Antimicrob. Agents Chemother. | pmid:10858369 |
| Kawai Y et al. | Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients. | 2013 | Antimicrob. Agents Chemother. | pmid:23459497 |
| Gunell M et al. | In vitro activity of azithromycin against nontyphoidal Salmonella enterica. | 2010 | Antimicrob. Agents Chemother. | pmid:20498312 |
| Carvalho-Assef AP et al. | Detection of NDM-1-, CTX-M-15-, and qnrB4-producing Enterobacter hormaechei isolates in Brazil. | 2014 | Antimicrob. Agents Chemother. | pmid:24449772 |
| Pfefferkorn ER and Borotz SE | Comparison of mutants of Toxoplasma gondii selected for resistance to azithromycin, spiramycin, or clindamycin. | 1994 | Antimicrob. Agents Chemother. | pmid:8141576 |
| Bermudez LE et al. | Rifabutin and sparfloxacin but not azithromycin inhibit binding of Mycobacterium avium complex to HT-29 intestinal mucosal cells. | 1994 | Antimicrob. Agents Chemother. | pmid:8067766 |
| Goldstein EJ et al. | Activities of HMR 3004 (RU 64004) and HMR 3647 (RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and eight other antimicrobial agents against unusual aerobic and anaerobic human and animal bite pathogens isolated from skin and soft tissue infections in humans. | 1998 | Antimicrob. Agents Chemother. | pmid:9593139 |
| Spangler SK et al. | Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococci. | 1998 | Antimicrob. Agents Chemother. | pmid:9593160 |
| Roblin PM and Hammerschlag MR | In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae. | 1998 | Antimicrob. Agents Chemother. | pmid:9624507 |
| Gelber RH et al. | Activities of various macrolide antibiotics against Mycobacterium leprae infection in mice. | 1991 | Antimicrob. Agents Chemother. | pmid:1648889 |
| Woosley LN et al. | CEM-101 activity against Gram-positive organisms. | 2010 | Antimicrob. Agents Chemother. | pmid:20176910 |
| Carter G et al. | A subinhibitory concentration of clarithromycin inhibits Mycobacterium avium biofilm formation. | 2004 | Antimicrob. Agents Chemother. | pmid:15561879 |
| Gnarpe J et al. | In vitro activities of azithromycin and doxycycline against 15 isolates of Chlamydia pneumoniae. | 1996 | Antimicrob. Agents Chemother. | pmid:8843291 |
| Edelstein PH et al. | In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia. | 2001 | Antimicrob. Agents Chemother. | pmid:11451675 |